{"id":378,"date":"2025-06-12T18:00:01","date_gmt":"2025-06-12T18:00:01","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=378"},"modified":"2026-09-01T16:08:45","modified_gmt":"2026-09-01T16:08:45","slug":"discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/","title":{"rendered":"SLU-PP-332 Peptide: Effects, Dosage &#038; Research Overview | Loti Labs"},"content":{"rendered":"<h1>SLU-PP-332: Mechanism of Action, Safety Data &amp; Research Applications<\/h1>\n<div class=\"ez-toc-v2_0_81 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\" id=\"ez-toc-container\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<p><span class=\"ez-toc-title-toggle\"><a aria-label=\"Toggle Table of Content\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" href=\"#\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg class=\"list-377408\" fill=\"none\" height=\"20px\" style=\"fill: #999;color:#999\" viewbox=\"0 0 24 24\" width=\"20px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg baseprofile=\"tiny\" class=\"arrow-unsorted-368013\" height=\"10px\" style=\"fill: #999;color:#999\" version=\"1.2\" viewbox=\"0 0 24 24\" width=\"10px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"><\/path><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav>\n<ul class=\"ez-toc-list ez-toc-list-level-1\">\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/#What_Is_SLU-PP-332\">What Is SLU-PP-332?<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/#History_and_Discovery_of_SLU-PP-332\">History and Discovery of SLU-PP-332<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/#Chemistry_and_Molecular_Structure\">Chemistry and Molecular Structure<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/#Mechanism_of_Action_How_SLU-PP-332_Activates_ERR%CE%B1\">Mechanism of Action: How SLU-PP-332 Activates ERR\u03b1<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/#Preclinical_Research_Findings\">Preclinical Research Findings<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/#SLU-PP-332_vs_5-Amino-1MQ_Comparative_Analysis\">SLU-PP-332 vs. 5-Amino-1MQ: Comparative Analysis<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/#Safety_Profile_and_Preclinical_Observations\">SLU-PP-332 Side Effects: Preclinical Safety Observations<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/#Legal_and_Regulatory_Status\">Legal and Regulatory Status<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/#Product_Specifications_and_Research_Availability\">Product Specifications and Research Availability<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/#Conclusion_and_Future_Research_Directions\">Conclusion and Future Research Directions<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/#References\">References<\/a><\/li>\n<\/ul>\n<\/nav>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_SLU-PP-332\"><\/span><span class=\"ez-toc-section\" id=\"What_Is_SLU-PP-332\"><\/span><span class=\"ez-toc-section\" id=\"what-is-slu-pp-332\"><\/span>What Is SLU-PP-332?<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p> Developed at Saint Louis University School of Medicine, SLU-PP-332 activates all three ERR isoforms (ERR\u03b1, ERR\u03b2, and ERR\u03b3) with preferential potency at ERR\u03b1 (EC<sub>50<\/sub> = 98 nM), making it one of the most well-characterized pan-ERR agonists available for laboratory research.<\/p>\n<p> The compound reproduces many of the gene-expression changes associated with aerobic exercise in preclinical models, offering investigators a controlled tool for studying these pathways without the confounding variables of physical activity protocols.<\/p>\n<p><strong>SLU-PP-332 is designated for laboratory and analytical research use only. It is not approved for human or veterinary use.<\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"History_and_Discovery_of_SLU-PP-332\"><\/span><span class=\"ez-toc-section\" id=\"History_and_Discovery_of_SLU-PP-332\"><\/span><span class=\"ez-toc-section\" id=\"history\"><\/span>History and Discovery of SLU-PP-332<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>SLU-PP-332 was first synthesized at the Saint Louis University (SLU) School of Medicine as part of a research initiative to develop novel modulators of estrogen-related receptors. The \u201cSLU-PP\u201d designation reflects its institutional origin. Early work by the Bhatt and Bhargava laboratories focused on creating selective ligands for ERRs \u2014 a receptor subfamily that, unlike classical estrogen receptors, lacks known endogenous ligands and had limited pharmacological tools available for study.<\/p>\n<p>The compound emerged from a series of structure-activity relationship (SAR) studies aimed at optimizing ERR agonist potency while maintaining pan-isoform activity. Key milestones in SLU-PP-332 research include:<\/p>\n<ul>\n<li><strong>Shahien et al. (2020)<\/strong> \u2014 Reported on the development of pan-ERR agonists as a class, establishing the chemical scaffold underlying SLU-PP-332.<\/li>\n<li><strong>Billon et al. <\/strong><\/li>\n<li><strong>Wansapura et al. <\/strong><\/li>\n<\/ul>\n<p>Funding for SLU-PP-332 development has included support from the National Institutes of Health (NIH), including the National Institute on Aging (NIA) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Research has also been supported by Washington University collaborators.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Chemistry_and_Molecular_Structure\"><\/span><span class=\"ez-toc-section\" id=\"Chemistry_and_Molecular_Structure\"><\/span><span class=\"ez-toc-section\" id=\"chemistry\"><\/span>Chemistry and Molecular Structure<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>SLU-PP-332, also designated by CAS number 303760-60-3, has the IUPAC name <em>4-hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide<\/em>. The molecule consists of a 4-hydroxybenzamide core linked to a naphthalene ring system via a hydrazone (C=N\u2013NH) bridge. The Z-configuration at the imine bond is critical for optimal interaction with the ERR ligand-binding domain (LBD).<\/p>\n<h3>Key Physicochemical Properties<\/h3>\n<ul>\n<li><strong>Molecular formula:<\/strong> C<sub>18<\/sub>H<sub>14<\/sub>N<sub>2<\/sub>O<sub>2<\/sub><\/li>\n<li><strong>Appearance:<\/strong> White to off-white solid<\/li>\n<li><strong>Purity:<\/strong> \u226598% (typical research-grade specification)<\/li>\n<li><strong>Solubility:<\/strong> Highly soluble in DMSO (75 mg\/mL); limited aqueous solubility<\/li>\n<li><strong>Storage:<\/strong> Stable for up to 2 years at \u221220\u00b0C under desiccated conditions<\/li>\n<\/ul>\n<p>The synthesis of SLU-PP-332 follows a two-step route: (1) esterification and hydrazinolysis of 4-hydroxybenzoic acid to form 4-hydroxybenzohydrazide, followed by (2) condensation with 2-naphthaldehyde to yield the active hydrazone product. This concise synthetic pathway allows for reproducible preparation of high-purity material suitable for analytical and in vivo research protocols.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_How_SLU-PP-332_Activates_ERR%CE%B1\"><\/span><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_How_SLU-PP-332_Activates_ERR%CE%B1\"><\/span><span class=\"ez-toc-section\" id=\"mechanism-of-action\"><\/span>Mechanism of Action: How SLU-PP-332 Activates ERR\u03b1<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>SLU-PP-332 functions as a ligand for estrogen-related receptors, binding to a hydrophobic trench adjacent to the ligand-binding domain (LBD) \u2014 with critical interactions involving residues Leu345 and Phe377 \u2014 and stabilizing the receptor\u2019s active conformation. <\/p>\n<h3>Receptor Binding Profile<\/h3>\n<p>SLU-PP-332 activates all three ERR subtypes with a preference for ERR\u03b1:<\/p>\n<ul>\n<li><strong>ERR\u03b1:<\/strong> EC<sub>50<\/sub> \u2248 98 nM<\/li>\n<li><strong>ERR\u03b2:<\/strong> EC<sub>50<\/sub> \u2248 215\u2013230 nM<\/li>\n<li><strong>ERR\u03b3:<\/strong> EC<sub>50<\/sub> \u2248 340\u2013430 nM<\/li>\n<\/ul>\n<p>This pan-ERR agonist profile distinguishes SLU-PP-332 from more selective ERR modulators. While ERR\u03b1 and ERR\u03b3 share overlapping target gene sets, they do not always produce identical downstream effects \u2014 a consideration researchers should weigh when selecting an ERR modulator for specific experimental questions.<\/p>\n<h3>Downstream Signaling Cascade<\/h3>\n<ul>\n<li><strong>PDK4<\/strong> (pyruvate dehydrogenase kinase 4) \u2014 shifts fuel utilization toward fatty acid oxidation<\/li>\n<li><strong>PGC-1\u03b1 pathway genes<\/strong> \u2014 drives mitochondrial biogenesis and oxidative capacity<\/li>\n<\/ul>\n<p>These transcriptional changes closely mirror the gene-expression signature observed after aerobic exercise bouts, which is why SLU-PP-332 is categorized as a pharmacological exercise mimetic in the research literature.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Preclinical_Research_Findings\"><\/span><span class=\"ez-toc-section\" id=\"Preclinical_Research_Findings\"><\/span><span class=\"ez-toc-section\" id=\"preclinical-research\"><\/span>Preclinical Research Findings<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3>Exercise Mimetic Activity in Murine Models<\/h3>\n<p>Billon et al. (2023) demonstrated that repeated administration of SLU-PP-332 to sedentary C57BL\/6J mice produced physiological adaptations typically associated with aerobic exercise training. Key observations included:<\/p>\n<ul>\n<li>Upregulation of ERR-dependent exercise gene programs<\/li>\n<li>Measurable pharmacokinetic exposure: plasma concentration of 0.2 \u03bcM and skeletal muscle concentration of 0.6 \u03bcM at 6 hours post-IP injection (30 mg\/kg)<\/li>\n<\/ul>\n<p>These findings established SLU-PP-332 as a functional exercise mimetic in preclinical models, capable of inducing training-like adaptations in the absence of physical activity.<\/p>\n<p>Wansapura et al. (2024, PMID: 37739806) extended this work to diet-induced obese (DIO) and <em>ob\/ob<\/em> mouse models. Administration of SLU-PP-332 produced the following observations:<\/p>\n<h3>Mitochondrial Function and Aging Research<\/h3>\n<p>SLU-PP-332 is also under investigation as a research tool for studying age-related mitochondrial decline. Mitochondrial dysfunction is a recognized hallmark of aging, and ERR-mediated pathways are central to mitochondrial quality control. Preclinical observations include:<\/p>\n<ul>\n<li>Modulation of mitochondrial dynamics and autophagy-related pathways<\/li>\n<\/ul>\n<p>These findings position SLU-PP-332 as a valuable laboratory tool for investigating the relationship between mitochondrial function, energy metabolism, and cellular aging.<\/p>\n<h3>Cardiac and Ischemia-Reperfusion Research<\/h3>\n<p>A study published in <em>Circulation<\/em> (DOI: 10.1161\/CIRCULATIONAHA.123.066542) examined SLU-PP-332 (compound 332) and a structurally distinct pan-ERR agonist (SLU-PP-915) in pressure overload\u2013induced heart failure models using transaortic constriction (TAC) in mice. Key findings included:<\/p>\n<ul>\n<li><strong>No suppression of hypertrophic signaling:<\/strong> Neither compound abrogated PE-induced ERK1\/2 phosphorylation or calcineurin\/NFAT signaling. <\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_5-Amino-1MQ_Comparative_Analysis\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_5-Amino-1MQ_Comparative_Analysis\"><\/span><span class=\"ez-toc-section\" id=\"comparison\"><\/span>SLU-PP-332 vs. 5-Amino-1MQ: Comparative Analysis<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p> Understanding these distinctions helps researchers select the appropriate compound for their experimental objectives.<\/p>\n<h3>Mechanism of Action<\/h3>\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>SLU-PP-332<\/th>\n<th>5-Amino-1MQ<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Target<\/strong><\/td>\n<td>ERR\u03b1 \/ ERR\u03b2 \/ ERR\u03b3 (nuclear receptor agonist)<\/td>\n<td>NNMT (nicotinamide N-methyltransferase inhibitor)<\/td>\n<\/tr>\n<tr>\n<td><strong>Primary pathway<\/strong><\/td>\n<td>PGC-1\u03b1 \u2192 mitochondrial gene transcription<\/td>\n<td>NAD\u207a elevation \u2192 SIRT1 \/ AMPK activation<\/td>\n<\/tr>\n<tr>\n<td><strong>Classification<\/strong><\/td>\n<td>Exercise mimetic (ERR agonist)<\/td>\n<\/tr>\n<tr>\n<td>Skeletal muscle, cardiac tissue, mitochondria<\/td>\n<td>Adipose tissue, liver, systemic NAD\u207a metabolism<\/td>\n<\/tr>\n<tr>\n<td><strong>Molecular weight<\/strong><\/td>\n<td>290.32 g\/mol<\/td>\n<td>158.18 g\/mol<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Research Applications<\/h3>\n<table>\n<thead>\n<tr>\n<th>Research Area<\/th>\n<th>SLU-PP-332<\/th>\n<th>5-Amino-1MQ<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Exercise biology<\/strong><\/td>\n<td>Strong \u2014 directly mimics aerobic exercise gene programs<\/td>\n<\/tr>\n<tr>\n<td><strong>Fat oxidation studies<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>NAD\u207a \/ sirtuins research<\/strong><\/td>\n<td>Indirect \u2014 downstream of ERR activation<\/td>\n<td>Direct \u2014 NNMT inhibition raises NAD\u207a levels<\/td>\n<\/tr>\n<tr>\n<td><strong>Aging research<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p> Some researchers use both compounds in parallel to investigate complementary metabolic pathways.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"SLU-PP-332_Side_Effects_Preclinical_Safety_Observations\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_Side_Effects_Preclinical_Safety_Observations\"><\/span><span class=\"ez-toc-section\" id=\"side-effects\"><\/span>SLU-PP-332 Side Effects: Preclinical Safety Observations<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>In preclinical animal models, SLU-PP-332 has not demonstrated significant adverse effects at research doses. The most commonly reported observations include transient cardiovascular changes (elevated heart rate) and mild gastrointestinal disturbances in murine subjects. No genotoxicity, hepatotoxicity, or organ-level toxicity has been reported in published preclinical studies to date. As an investigational compound with no human clinical trial data, all safety data referenced here derives from in vitro and animal model research.<\/p>\n<p>Understanding the safety profile of SLU-PP-332 is critical for researchers designing preclinical studies. The following summarizes what is currently known from published laboratory data:<\/p>\n<h3>Reported Preclinical Findings<\/h3>\n<ul>\n<li><strong>No reported hepatotoxicity, nephrotoxicity, or acute organ toxicity<\/strong> in published rodent studies at standard research concentrations (10\u201350 mg\/kg, IP administration)<\/li>\n<li><strong>No hormonal suppression or estrogenic activity<\/strong> \u2014 ERRs are structurally related to estrogen receptors but do not bind estrogens, and SLU-PP-332 does not activate classical estrogen receptor signaling<\/li>\n<li><strong>Good pharmacokinetic exposure<\/strong> \u2014 measurable plasma and tissue concentrations with adequate duration for in vivo research protocols<\/li>\n<\/ul>\n<h3>Research Considerations<\/h3>\n<p>Several aspects warrant attention in experimental design:<\/p>\n<ul>\n<li><strong>Pan-ERR activation and ERR\u03b3:<\/strong> SLU-PP-332 activates all three ERR isoforms. <\/li>\n<li><strong>Limited aqueous solubility:<\/strong> SLU-PP-332 requires DMSO as a vehicle for most experimental applications. Standard DMSO vehicle controls should be included in all study designs.<\/li>\n<li><strong>Comprehensive toxicology data remain limited:<\/strong> While no adverse findings have been reported in the published literature, formal GLP-grade toxicology studies have not been published as of the time of writing. Researchers should exercise standard precautions for investigational compounds.<\/li>\n<\/ul>\n<h3>Laboratory Handling Protocols<\/h3>\n<p>Standard safety protocols apply when working with SLU-PP-332:<\/p>\n<ul>\n<li>Use appropriate PPE (gloves, lab coat, eye protection) during handling<\/li>\n<li>Prepare solutions in a well-ventilated area or chemical fume hood<\/li>\n<li>Store reconstituted aliquots at \u221220\u00b0C to prevent degradation<\/li>\n<li>Consult the compound\u2019s Safety Data Sheet (SDS) for complete handling guidance<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Legal_and_Regulatory_Status\"><\/span><span class=\"ez-toc-section\" id=\"Legal_and_Regulatory_Status\"><\/span><span class=\"ez-toc-section\" id=\"legal-status\"><\/span>Legal and Regulatory Status<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>SLU-PP-332 is classified as a research compound and has not received approval from the FDA or any other regulatory body for use in humans or animals outside of laboratory settings. It is designated for <strong>in vitro<\/strong> and <strong>in vivo<\/strong> research use only, in compliance with applicable institutional review board (IRB) and institutional animal care and use committee (IACUC) guidelines.<\/p>\n<p>Laboratories incorporating SLU-PP-332 into their research programs should verify that their intended use aligns with institutional protocols and governmental regulations. All work should be conducted under appropriate oversight with full documentation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Product_Specifications_and_Research_Availability\"><\/span><span class=\"ez-toc-section\" id=\"Product_Specifications_and_Research_Availability\"><\/span><span class=\"ez-toc-section\" id=\"product-specs\"><\/span>Product Specifications and Research Availability<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Research-grade SLU-PP-332 is available from specialized suppliers for laboratory use. Key specifications include:<\/p>\n<ul>\n<li><strong>Form:<\/strong> White to off-white lyophilized solid<\/li>\n<li><strong>Purity:<\/strong> \u226598% (verified by HPLC)<\/li>\n<li><strong>Solubility:<\/strong> DMSO (75 mg\/mL); prepare working solutions fresh or store aliquots at \u221220\u00b0C<\/li>\n<li><strong>Storage conditions:<\/strong> \u221220\u00b0C, desiccated, protected from light<\/li>\n<li><strong>Stability:<\/strong> Up to 2 years under recommended storage conditions<\/li>\n<li><strong>Certificate of Analysis (COA):<\/strong> Available from reputable suppliers with each lot<\/li>\n<\/ul>\n<p>Loti Labs supplies <a href=\"https:\/\/lotilabs.com\/product\/slu-pp-332-liquid-25mg-per-ml\/\">research-grade SLU-PP-332 (25 mg\/mL liquid formulation)<\/a> with a Certificate of Analysis (COA) provided for each lot. All products are verified to \u226598% purity by HPLC and shipped under cold-chain conditions to preserve compound integrity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_and_Future_Research_Directions\"><\/span><span class=\"ez-toc-section\" id=\"Conclusion_and_Future_Research_Directions\"><\/span><span class=\"ez-toc-section\" id=\"conclusion\"><\/span>Conclusion and Future Research Directions<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>SLU-PP-332 has emerged as one of the most thoroughly characterized pan-ERR agonists in the preclinical research landscape. <\/p>\n<p>Active and emerging areas of investigation include:<\/p>\n<ul>\n<li><strong>Combinatorial metabolic studies<\/strong> \u2014 pairing SLU-PP-332 with other metabolic modulators (e.g., 5-Amino-1MQ, AICAR) to map complementary pathway interactions<\/li>\n<li><strong>Formulation optimization<\/strong> \u2014 addressing aqueous solubility limitations for expanded in vivo research applications<\/li>\n<\/ul>\n<p>As the body of published data on SLU-PP-332 continues to grow, this compound is expected to remain a foundational research tool for laboratories investigating ERR biology, exercise physiology, and mitochondrial function.<\/p>\n<p><em><a href=\"https:\/\/lotilabs.com\/product\/slu-pp-332-liquid-25mg-per-ml\/\">SLU-PP-332<\/a> is supplied by Loti Labs for laboratory and analytical research use only. Not for human or veterinary use.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"references\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li>Billon C, Sitaula S, Burris TP. 2016;5(10):997\u20131005.<\/li>\n<li>Billon C, et al. <em> 2024 (reference therein).<\/em><\/li>\n<li>Wansapura J, et al. 2024;388(2):232\u2013240. PMID: 37739806. DOI: 10.1124\/jpet.123.001733.<\/li>\n<li>Shahien AA, et al. (2020). Development of pan-ERR agonists. <em>Referenced in Wansapura et al. 2024.<\/em><\/li>\n<li>Mao L, et al. (2022). <em>Referenced in Wansapura et al. 2024.<\/em><\/li>\n<li> 2023. DOI: 10.1161\/CIRCULATIONAHA.123.066542.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><span class=\"ez-toc-section\" id=\"faq\"><\/span>Frequently Asked Questions<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 class=\"wp-block-heading\">What are the primary research applications of SLU-PP-332?<\/h3>\n<p> It serves as a pharmacological exercise mimetic.<\/p>\n<h3 class=\"wp-block-heading\">How is SLU-PP-332 typically administered in laboratory studies?<\/h3>\n<p>In murine models, SLU-PP-332 is commonly administered via intraperitoneal (IP) injection. It requires dissolution in organic solvents like DMSO due to limited aqueous solubility. Researchers must include appropriate vehicle controls in their study designs.<\/p>\n<h3 class=\"wp-block-heading\">Are there any known side effects of SLU-PP-332 in preclinical research models?<\/h3>\n<p>Preclinical research suggests SLU-PP-332 has a favorable tolerability profile at standard research doses. See the <a href=\"#side-effects\">SLU-PP-332 Side Effects section<\/a> above for a full summary of reported preclinical observations, including cardiovascular and gastrointestinal findings from murine models.<\/p>\n<h3 class=\"wp-block-heading\">What is the recommended dosage range for SLU-PP-332 in <em>in vivo<\/em> research models?<\/h3>\n<p> Specific dosages may vary based on the model, duration, and research objective.<\/p>\n<h3 class=\"wp-block-heading\">How does SLU-PP-332 compare to other exercise mimetics like AICAR or GW501516?<\/h3>\n<p>SLU-PP-332 activates Estrogen-Related Receptors (ERRs), driving mitochondrial biogenesis. <\/p>\n<p><script type=\"application\/ld+json\">\n{\n \"@context\": \"https:\/\/schema.org\",\n \"@graph\": [\n {\n \"@type\": \"ScholarlyArticle\",\n \"mainEntityOfPage\": {\n \"@type\": \"WebPage\",\n \"@id\": \"https:\/\/lotilabs.com\/resources\/slu-pp-332-comprehensive-guide\/\"\n },\n \"headline\": \"SLU-PP-332: Mechanism of Action, Safety Data & Research Applications\",\n \"description\": \"Explore SLU-PP-332, a pan-ERR agonist and exercise mimetic. Discover its mechanism of action, preclinical safety, metabolic effects, and research applications in mitochondrial function, obesity, and aging.\",\n \"datePublished\": \"2025-06-12\",\n \"dateModified\": \"2026-04-28\",\n \"author\": {\n \"@type\": \"Organization\",\n \"name\": \"Loti Labs\",\n \"url\": \"https:\/\/lotilabs.com\/\"\n },\n \"publisher\": {\n \"@type\": \"Organization\",\n \"name\": \"Loti Labs\",\n \"url\": \"https:\/\/lotilabs.com\/\"\n },\n \"keywords\": [\n \"SLU-PP-332\",\n \"ERR agonist\",\n \"exercise mimetic\",\n \"mitochondrial biogenesis\",\n \"metabolic research\",\n \"ERRalpha\",\n \"PGC-1alpha\"\n ],\n \"articleSection\": [\n \"What Is SLU-PP-332?\",\n \"History and Discovery of SLU-PP-332\",\n \"Chemistry and Molecular Structure\",\n \"Mechanism of Action\",\n \"Preclinical Research Findings\",\n \"SLU-PP-332 Side Effects: Preclinical Safety Observations\",\n \"Legal and Regulatory Status\"\n ]\n },\n {\n \"@type\": \"FAQPage\",\n \"mainEntity\": [\n {\n \"@type\": \"Question\",\n \"name\": \"What are the primary research applications of SLU-PP-332?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"SLU-PP-332 is primarily used in preclinical research to study exercise-induced metabolic adaptations, mitochondrial biogenesis, fatty acid oxidation, and its potential roles in metabolic syndrome, obesity, and age-related mitochondrial decline. It serves as a pharmacological exercise mimetic.\"\n }\n },\n {\n \"@type\": \"Question\",\n \"name\": \"How is SLU-PP-332 typically administered in laboratory studies?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"In murine models, SLU-PP-332 is commonly administered via intraperitoneal (IP) injection. It requires dissolution in organic solvents like DMSO due to limited aqueous solubility. Researchers must include appropriate vehicle controls in their study designs.\"\n }\n },\n {\n \"@type\": \"Question\",\n \"name\": \"Are there any known side effects of SLU-PP-332 in preclinical research models?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"Published preclinical studies have not reported hepatotoxicity, nephrotoxicity, acute organ toxicity, or hormonal suppression at standard research concentrations. However, comprehensive GLP toxicology data are limited, and ERR\u03b3 activation has been associated with cardiac hypertrophy markers in some contexts.\"\n }\n },\n {\n \"@type\": \"Question\",\n \"name\": \"What is the recommended dosage range for SLU-PP-332 in in vivo research models?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"In published murine studies, SLU-PP-332 has been effectively used at doses ranging from 10 mg\/kg to 50 mg\/kg, with 30 mg\/kg (IP) being a frequently reported effective dose for inducing exercise-like adaptations.\"\n }\n },\n {\n \"@type\": \"Question\",\n \"name\": \"How does SLU-PP-332 compare to AICAR or GW501516?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"SLU-PP-332 activates Estrogen-Related Receptors (ERRs), driving mitochondrial biogenesis. AICAR activates AMPK, modulating glucose and lipid metabolism. GW501516 (Cardarine) is a PPAR\u03b4 agonist known for fat oxidation and endurance. Each targets different pathways, offering distinct research tools for studying exercise physiology.\"\n }\n }\n ]\n }\n ]\n}\n<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Complete research guide on SLU-PP-332 \u2014 an ERR\u03b1 agonist exercise mimetic. Covers mechanism of action, safety profile, research applications, and comparison to 5-Amino-1MQ. For laboratory research use only.<\/p>\n","protected":false},"author":1,"featured_media":371,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-378","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=378"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/378\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/371"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}